Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job’s syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin

Cunha, Burke A.; Krol, Vitaliy; Kodali, Visali

doi:10.1016/j.hrtlng.2007.04.003

Cited by 30 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date there are limited clinical data for the use of daptomycin at doses >6 mg/kg [9][10][11][12][13]. In particular, there are no studies comparing the clinical and microbiological efficacies of higher doses with standard doses.…”

Section: Discussionmentioning

confidence: 99%

“…20 g/mL, suggesting that this regimen might have sufficient activity against organisms with higher MICs [8]. Clinical experiences with doses >6 mg/kg are limited, but data reported to date suggest that daptomycin appears to be safe and well tolerated even at higher doses [9][10][11][12][13]. A recent study of experimental foreign-body meticillin-resistant S. aureus infection suggested that high-dose daptomycin (10 mg/kg/day) ensured a profile of safety from the development of resistance [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High-dose daptomycin in documented Staphylococcus aureus infections

Bassetti

Nicco

Ginocchio

et al. 2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Daptomycin is approved at a dose of 4-6 mg/kg/day for the treatment of complicated skin and soft-tissue infection and Staphylococcus aureus bloodstream infection. Clinical experience with doses >6 mg/kg/day is limited, but data reported to date suggest that daptomycin can be safe and effective at higher doses. We describe our experience with daptomycin at doses >6 mg/kg/day and ≤6 mg/kg/day for S. aureus infections. A retrospective chart review of all patients treated with daptomycin from January 2008 to 28 February 2010 was performed. During the study period, 53 patients received daptomycin, including 22 patients receiving daptomycin at a standard dose (SD) (mean 5 mg/kg/day, range 4-6 mg/kg/day) and 31 patients receiving a higher dose (HD) (mean 8 mg/kg/day, range 7-9 mg/kg). The median treatment duration was 13.5 days and 19 days for the SD and HD groups, respectively. Clinical success was observed in 16/22 patients (73%) in the SD group and 29/31 patients (94%) in the HD group (P=0.05). Microbiological success was observed in 13/19 patients (68%) and 27/29 patients (93%) in the SD and HD groups, respectively (P<0.05). Of the 53 patients, 2/22 treated with SD daptomycin and 3/31 treated with HD daptomycin experienced a grade 1 adverse event while receiving therapy (i.e. anaemia, diarrhoea, nausea, hypokalaemia and arthralgia) but did not require discontinuation of daptomycin treatment. These results suggest that daptomycin may be used at doses higher than 6 mg/kg/day without toxicity and possibly with better outcome than conventional doses. We recommend further randomised controlled prospective studies with higher doses of daptomycin.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

High-dose daptomycin in documented Staphylococcus aureus infections

Bassetti

Nicco

Ginocchio

et al. 2010

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

show abstract

“…Multiple cases of patients treated with high-dose daptomycin have also been reported in the literature [16][17][18][19][20]. Some investigators have attributed clinical success to the increased daptomycin dosage [16,20] Doses between 8 mg/kg/q24 and 12 mg/kg/q24 have been utilised for the treatment of acute bacterial MRSA endocarditis, MRSA bacteraemia, vancomycin-resistant Enterococcus faecium endocarditis and prosthetic infections for prolonged periods [16,17,19,20].…”

Section: Case Reportsmentioning

confidence: 99%

“…Some investigators have attributed clinical success to the increased daptomycin dosage [16,20] Doses between 8 mg/kg/q24 and 12 mg/kg/q24 have been utilised for the treatment of acute bacterial MRSA endocarditis, MRSA bacteraemia, vancomycin-resistant Enterococcus faecium endocarditis and prosthetic infections for prolonged periods [16,17,19,20]. In these reports, the patients did not experience adverse events or CPK elevations as a result of the high-dose regimens [16][17][18][19][20]. These case reports provide further evidence in support of clinical benefit without increased toxicities when utilising a high-dose daptomycin treatment strategy.…”

Section: Case Reportsmentioning

confidence: 99%

“…Unfortunately, clinical failures and resistant strains have already been reported with daptomycin [9][10][11]. Consequently, doses greater than the approved dosing are being considered as an alternative (Table 1) [5,[12][13][14][15][16][17][18][19][20]. Higher doses may take advantage of the pharmacokinetic (PK) profile of daptomycin and its concentrationdependent activity [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation